It is always interesting to see what happens on ADR trading in the home markets when U.S. stock markets are closed. Martin Luther King Day brings a closure of the U.S. markets, but all other major global markets and exchanges are open for normal trading. At least it is considered normal, but without the liquidity of U.S. market participants in their local exchanges.
BlackBerry Ltd. (NASDAQ: BBRY) already had a great Friday in New York trading. Its shares gained just over 6% to $9.08, based on Citron Research putting out a change of sentiment report. Usually that report is negative and better known for short selling candidates, but the publication called out that things have reversed and that the company formerly known as Research In Motion could see its shares rise to at least $15.
Many U.S. investors forget that BlackBerry is Canadian, and its home market is the Toronto Stock Exchange. Its shares rose 6.5% to C$9.98 in Toronto on Friday (versus $9.08 close in New York). Shares were up 15% in Toronto trading on Monday’s mid-morning session�to C$11.50. On a static basis, this would equate to a BlackBerry price of close to $10.46 in New York for Tuesday. Again, static means assuming no further changes — and markets do tend to change.
Top 5 Casino Companies To Buy Right Now: Gilead Sciences Inc.(GILD)
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 1987 and is headquartered in Fost er City, California.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Gilead Sciences�(GILD) fell 3.6% today, and the experts I spoke with said that they didn’t see a catalyst for the drop, one that dragged the entire biotech sector down with it.
Now there are two possibilities. StreetInsider.com and the Fly On the Wall both referred to a voluntary recall of Gilead’s HIV-drug Atripla, though both made referencer to a Deutsche Bank report that dismissed the recall as minor and unlikely to have a major impact.
But there’s another possibility. Citigroup’s Yaron Weber explains:
Today, at the CROI meeting, data from the NEAT 001/ANRS143 trial testing the combination of Isentress + Prezista/ritonavir (ie nuc sparing) in 805 new HIV patients showed non-inferiority to Prezista/ritonavir + Gilead’s Truvada.
It looks to us that there is finally some legitimate competitor to Gilead�� HIV regimens that could be cheaper and viable for 85% of patients. However, the Isentress/Prezista regimen will require more pills/day and will have more side effects. At this point, a formal development plan will need to be undertaken by either Merck or JNJ or both to support registration of this regimen. As the standard of care is shifting, they might also need to test the regimen against Gilead�� Stribild. As such, we do not anticipate that this regimen will be licensed until at least another 2-3 years.�
Whatever the reason, the day was clearly a painful one for biotech investors, who have already been facing charges of bubble-mania in the sector. The SPDR S&P Biotech ETF (XBI) fell 3.1%, the iShares Nasdaq Biotechnology Index ETF (IBB) dropped 2.7%, while Amgen (AMGN) fell 1.6% and Regeneron Pharmaceuticals (REGN) declined 2%.
- [By Ben Levisohn]
Last week, investors freaked out when biotech giant Gilead (GILD) announced its 2014 outlook and didn’t include Sovaldi in its calculations.
Getty ImagesArgus analyst David Toung explains why Sovaldi would make the Gilead’s numbers look even better:
In issuing guidance for 2014, Gilead notably excluded any sales from Sovaldi, even though it has been approved in the U.S., Canada and Europe. It expects 2014 sales from core products, excluding Sovaldi, of $11.3-$11.5 billion, an increase of 6%- 8% from 2013. It also projects a product gross margin of 75%-77%. It did not provide specific EPS guidance. Management expects to increase sales and marketing spending to support the launch of Idelalisib, its first oncology drug. It also expects to increase R&D spending to develop its product pipeline. As for Sovaldi, Gilead noted that every $1 billion of incremental Sovaldi sales would increase the gross margin by 75- 100 basis points and reduce the tax rate by 75-100 basis point
We are raising our 2014 EPS estimate to $3.35 from $3.25, and establishing a 2015 estimate of $5.10. Our revised earnings model includes contributions from Sovaldi and Idelalisib as well as ongoing growth from core pharmaceutical products. We also note the favorable impact from Sovaldi sales on Gilead�� gross margin and tax rate.
Shares of Gilead have gained 2.4% to $80.64 at 2:31 p.m., easily outpacing Amgen�(AMGN), which has risen 0.6% to $119.64,�Biogen Idec�(BIIB), which has advance0.5% to $317.14 and�Celgene, (CELG) is off 0.1% to $156.75. The SPDR S&P Biotech ETF�(XBI) has fallen jumped 2.6% to $153.43.
5 Best Electric Utility Stocks To Invest In 2014: Service Corporation International (SVC)
Service International Corp., formerly Service Corporation International, incorporated in July 1962, is a provider of deathcare products and services, with a network of funeral service locations and cemeteries primarily operating in the United States and Canada. Its operations consist of funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and related businesses. The Company operates in two segments: funeral and cemetery operations. At December 31, 2011, it operated 1,423 funeral service locations and 374 cemeteries (including 214 funeral service/cemetery combination locations) in North America, which are geographically diversified across 43 states, eight Canadian provinces, and the District of Columbia. Its funeral service and cemetery operations consist of funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and related businesses. The Company sells cemetery property and funeral and cemetery products and services at the time of need and on a preneed basis. In December 2013, the Company announced that it completed its acquisition of Stewart Enterprises, Inc. In May 2014, Carriage Services, Inc. acquired six businesses in New Orleans and Alexandria, Virginia from Service Corporation International.
The Company�� funeral service and cemetery operations consist of funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and related businesses. The Company provides all professional services relating to funerals and cremations, including the use of funeral facilities and motor vehicles and preparation and embalming services. Funeral-related merchandise, including caskets, casket memorialization products, burial vaults, cremation receptacles, cremation memorial products, flowers, and other ancillary products and services, is sold at funeral service locations. Its cemeteries provide cemetery property interment rights, including mausoleum spaces, lots, and lawn cr! ypts, and sell cemetery-related merchandise and services, including stone and bronze memorials, markers, merchandise installations, and burial openings and closings. The Company also sells preneed funeral and cemetery products and services whereby a customer contractually agrees to the terms of certain products and services to be delivered and performed in the future.
During the year ended December 31, 2011, its operations in the United States and Canada were organized into 29 major markets, 47 metro markets, and 78 main street markets. At December 31, 2011, it owned approximately 89% of the real estate and buildings used at its facilities, and the remainder of the facilities were leased. At December 31, 2011, its 374 cemeteries contained a total of approximately 26,540 acres, of which approximately 60% was developed.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
From a struggling department store chain delivering better than expected financial results to a popular photo-printing services provider botched a mass mailing, here's a rundown of the week's smartest moves and biggest blunders in the business world. Keurig Green Mountain (GMCR) -- Winner Coca-Cola (KO) is apparently a coffee addict. The world's leading beverage company turned heads earlier this year when it paid $1.25 billion for a 10 percent stake in Keurig Green Mountain. This week it announced that it's bumping its stake to 16 percent, paying a much higher price for the new shares. Keurig Green Mountain is the company behind the country's most popular single-serve coffee maker. In a few months it plans to enter the carbonated beverage market with Keurig Cold. Coca-Cola is on board to provide soft drink flavors for the machine, and now the company has a greater stake in seeing that Keurig Cold is successful. Shutterfly (SFLY) -- Loser "There's nothing more amazing than bringing a new life into the world," begins a promotion that Shutterfly mailed out this week. "As a new parent you're going to find more to love, more to give and more to share -- we're here to help you every step of the way." Shutterfly intended for the mailing to go out to customers who had recently ordered birth announcements, reminding them that matching thank you cards are now in order for the family and friends who provided gifts for the new baby. The problem here is that the marketing email went out to a far wider base of Shutterfly registered users. Twitter and Facebook were alive with folks joking or complaining about the mishap. It was an amusing blunder for most recipients, but it's easy to see how this kind of missive could hit hard to others. Netflix (NFLX) -- Winner We're apparently a nation of Netflix addicts. Online trend watcher Sandvine (SVC) reports that the streaming video service accounted for 34.2 percent of the North America's peak downstream Internet traffic durin
5 Best Electric Utility Stocks To Invest In 2014: Cott Corp (COT)
Cott Corporation (Cott), incorporated on December 31, 2006, is a producers of beverages on behalf of retailers, brand owners and distributors. The Company�� product lines include carbonated soft drinks (CSDs), 100% shelf stable juice and juice-based products, clear, still and sparkling flavored waters, energy products, sports products, new age beverages, and ready-to-drink teas, as well as alcoholic beverages for brand owners. The Company operates in five segments: North America (which includes the United States operating segment and Canada operating segment), the United Kingdom (which includes its United Kingdom reporting unit and its Continental European reporting unit), Mexico, Royal Crown International (RCI) and All Other. The Company markets or supplies over 500 retailer, licensed and Company-owned brands in its four core geographic segments. In March of 2012, its U.K. reporting segment acquired a beverage and wholesale business based in Scotland.
Advisors' Opinion:- [By kcpl]
It wasn�� a good quarter for Cott Corporation (COT) as the company had trouble with its volumes. Cott Corporation engages in the production and distribution of retailer brand beverages in North America and globally. It offers carbonated soft drinks, flavored waters, energy-related drinks, juice, juice-based products, bottled water and ready-to-drink teas. It primarily serves grocery, mass-merchandise, drugstore, wholesale and convenience store chains.
- [By Dan Moskowitz]
Cott (NYSE: COT ) produces and sells over 200 different types of beverages in over 50 countries, and it implements a highly effective strategy. Cott is what is known as a Fast Follower, which makes it unique to other beverage companies.�
5 Best Electric Utility Stocks To Invest In 2014: China New Borun Corporation (BORN)
China New Borun Corporation, through its subsidiaries, engages in the production and distribution of corn-based edible alcohol in the People�s Republic of China. Its edible alcohol products are primarily sold as ingredients to producers of baijiu, which a grain-based alcoholic beverage to further blend them into finished products that are sold under various brand names in retail stores, bars, banquet halls, restaurants, and other locations. The company also produces distillers dried grains with solubles (DDGS) feed, corn germ, crude corn oil, and liquid carbon dioxide as by-products during the production of edible alcohol. The company was founded in 2000 and is based in Shouguang, the People's Republic of China. China New Borun Corporation is a subsidiary of King River Holding Limited.
Advisors' Opinion:- [By James E. Brumley]
With a market cap of only $60 million and practically no trading volume until last month, odds are good you and most of your trading friends have ever even heard of China New Borun Corp. (NYSE:BORN). That doesn't mean it can't become a good trading opportunity, however. In fact, BORN has become a good trading opportunity, especially this week.
No comments:
Post a Comment